Dr. Thierry Jacquemin Expands His Innovative Approach to Health, Performance, and Aesthetic Wellness
As demand for personalized, science-backed wellness solutions continues to rise, Dr. Thierry Jacquemin is expanding his ...
The AACR poster presentation will provide an update on the data in AML patients most recently presented at the American Society of Hematology (ASH) Annual Meeting 2024 showing that ICT01 administered ...
Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for ...
Rani Therapeutics will host a conference call and live webcast at 4:30 p.m. ET / 1:30 p.m. PT on March 31, 2025. Individuals interested in listening to the live conference call may do so by using the ...
COO and President Ramses Erdtmann continuing at Biomea in current role.
Time frame The share buy-back program will start on March 26, 2025, and is expected to end no later than July 10, 2025 (unless Genmab terminates or suspends the program).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback